Phase I pharmacokinetic study of ECO-4601, a novel bifunctional targeting agent
...apeutic threshold, says Pierre Falardeau, Ph.D., chief operating officer at thallion Pharmaceuticals in Montreal, Canada. thallion has produced and tested ECO-4601 in association with the Segal Cancer Centr...Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
... MONTRÉAL, June 1, 2007 – thallion Pharmaceuticals Inc. (TSX: TLN) announced today th... McGill University in Montreal in conjunction with thallion Pharmaceuticals Inc. The abstract is titled: &ld...ry genomics-based drug discovery platform. About thallion Pharmaceuticals Inc....Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
...ous senior clinical and regulatory affairs roles at Merck & Co. in the US and abroad. In addition to serving on the Board of Directors for IDM Pharma, thallion Pharmaceuticals and Cubist Pharmaceuticals, she was recently appointed to the Board of Directors of the Greater Boston Food Bank. She is also on the B...